Showing results (421-430 of 587) with videos related to

Sort By:
Pageof 59
Oncotarget|June 11, 2016
Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinomaAskar Obulkasim, Bauke Ylstra, Hendrik F van Essen, et al.
The Lancet. Oncology|August 9, 2017
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trialDerek Alderson, David Cunningham, Matthew Nankivell, et al.
British Journal of Haematology|November 28, 2024
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waitingMaria A V Marzolini, Wendi Qian, Laura Clifton-Hadley, et al.
The Lancet. Haematology|April 12, 2016
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 studySandy Amorim, Anastasios Stathis, Mary Gleeson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy TrialElizabeth C Smyth, Matteo Fassan, David Cunningham, et al.
Oncotarget|October 22, 2016
Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trialMatthew D Hale, Matthew Nankivell, Gordon G Hutchins, et al.
BMC Cancer|March 21, 2023
ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)Susanna Slater, Annette Bryant, Hsiang-Chi Chen, et al.
Genetic Epidemiology|July 20, 2011
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impactRobert J Macinnis, Antonis C Antoniou, Rosalind A Eeles, et al.
European Journal of Cancer (Oxford, England : 1990)|January 27, 2022
Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimensJonathan L Moore, Sacheen Kumar, Aida Santaolalla, et al.
BMC Cancer|April 26, 2023
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centreDavid K Lau, Caroline Fong, Faten Arouri, et al.
Pageof 59